Cubist Boosts Cubicin Sales Reps, Will Detail 80% Of Vancomycin Prescribers
Executive Summary
Cubist will increase its Cubicin (daptomycin) sales force by one third in the first quarter, bringing the total to 100 reps, CEO Michael Bonney said
You may also be interested in...
Cubicin Resistance Should Be Closely Monitored In Bacteremia Patients
Labeling regarding use of Cubist's anti-infective Cubicin in Staphylococcus aureus patients should include a recommendation for close monitoring for development of resistance, members of FDA's Anti-Infective Drugs Advisory Committee said March 6
Cubicin Resistance Should Be Closely Monitored In Bacteremia Patients
Labeling regarding use of Cubist's anti-infective Cubicin in Staphylococcus aureus patients should include a recommendation for close monitoring for development of resistance, members of FDA's Anti-Infective Drugs Advisory Committee said March 6
Cubist expands hospital sales force
Cubist will begin increasing its anti-infective acute care U.S. sales force from 99 to 135 reps immediately, the firm announced Nov. 22. The expansion follows a Nov. 21 decision by FDA to grant priority review to the company's sNDA for Cubicin in treatment of endocarditis and bacteremia caused by Staphylococcus aureus (1"The Pink Sheet" March 7, 2005, p. 39). The sales realignment, effective Jan. 1, will focus on increasing coverage for the broadened indication...